FDA Commissioner Marty Makary announced that Dr. Vinay Prasad, head of the Center for Biological Evaluation and Research (CBER), will depart at the end of April. This marks the second time in less than a year that Prasad has left the agency — he was fired in July 2025 over his handling of a Duchenne muscular dystrophy treatment, then rehired weeks later with backing from Health Secretary RFK Jr.

Prasad's tenure has been marked by clashes with the pharmaceutical industry. His center rejected at least five cell and gene therapies that experts believe would have been approved under previous leadership. Most notably, he initially blocked the FDA from reviewing Moderna's mRNA flu vaccine — an unprecedented move that was reversed within a week after public backlash. Multiple drugmakers accused CBER of reversing prior agreements on clinical trial designs.

His departure adds to significant leadership instability at the FDA, where the Center for Drug Evaluation and Research cycled through five directors in 2025 alone.